Bullous Pemphigoid Clinical Trial
Official title:
Assessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid.
The aim of the study is to assess that it will be possible to control with a single cycle of rituximab patient with bullous pemphigoid.
The objective of this study is to assess the efficacy and tolerance of a single cycle of
rituximab in control of bullous pemphigoid.
the main objects are :
1. to assess that a single cycle of rituximab is able to control patient with
corticosteroid-dependent bullous pemphigoid,
2. to avoid the use of corticosteroid in long time,
3. to evaluate duration of control disease and side effect with a single cycle of
rituximab.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03286582 -
A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid
|
Phase 2 | |
| Completed |
NCT02837965 -
Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid
|
||
| Recruiting |
NCT03636763 -
Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?
|
||
| Recruiting |
NCT00802243 -
Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid
|
Phase 2 | |
| Completed |
NCT05649579 -
Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid
|
||
| Active, not recruiting |
NCT04206553 -
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
|
Phase 2/Phase 3 | |
| Completed |
NCT00431119 -
Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid
|
Phase 2 | |
| Completed |
NCT04563923 -
Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody
|
Phase 2 | |
| Completed |
NCT03320798 -
Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients
|
N/A | |
| Completed |
NCT03272958 -
Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid
|
||
| Completed |
NCT02883894 -
Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid
|
N/A | |
| Completed |
NCT00809822 -
Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.
|
Phase 2 | |
| Recruiting |
NCT05594472 -
Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid
|
Phase 3 | |
| Withdrawn |
NCT05061771 -
Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
|
Phase 3 | |
| Not yet recruiting |
NCT04128176 -
Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid
|
Phase 3 | |
| Recruiting |
NCT05284929 -
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
|
||
| Terminated |
NCT04612790 -
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
|
Phase 3 | |
| Recruiting |
NCT05681481 -
A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
|
Phase 3 | |
| Completed |
NCT00286325 -
Rituximab in the Treatment of Patients With Bullous Pemphigoid
|
Phase 1/Phase 2 | |
| Completed |
NCT04728854 -
Telederm and Bullous Pemphigoid
|